Wall Street Zen Upgrades Jupiter Neurosciences (NASDAQ:JUNS) to Sell

Jupiter Neurosciences (NASDAQ:JUNS) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Jupiter Neurosciences Stock Down 1.1%

Jupiter Neurosciences stock opened at $5.18 on Friday. The company has a 50 day moving average of $12.68 and a 200-day moving average of $24.72. Jupiter Neurosciences has a twelve month low of $4.56 and a twelve month high of $137.96. The stock has a market capitalization of $3.99 million, a PE ratio of -0.27 and a beta of 1.99.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings data on Friday, August 14th. The company reported ($5.06) EPS for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.40 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Allen Capital Group LLC bought a new position in Jupiter Neurosciences in the fourth quarter valued at $31,000. Yorkville Advisors Global LP bought a new stake in Jupiter Neurosciences during the 4th quarter worth about $135,000. Geode Capital Management LLC lifted its position in Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after buying an additional 28,826 shares in the last quarter. Finally, Vestor Capital LLC boosted its stake in shares of Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after buying an additional 970,314 shares during the last quarter.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.